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Harmonization study between three 
laboratories for expression of malaria vaccine 
clinical trial IgG antibody ELISA data in µg/mL
Geneviève M. Labbé1†, Kazutoyo Miura2†, Sarah E. Silk1, Wenjuan Gu3, James E. Moon4, Jing Jin1, Ruth O. Payne1, 
Michael P. Fay3, Sheetij Dutta4, Carole A. Long2 and Simon J. Draper1* 
Abstract 
Background: The ability to report vaccine-induced IgG responses in terms of µg/mL, as opposed arbitrary units (AU), 
enables a more informed interpretation of the magnitude of the immune response, and better comparison between 
vaccines targeting diferent antigens. However, these interpretations rely on the accuracy of the methodology, which 
is used to generate ELISA data in µg/mL. In a previous clinical trial of a vaccine targeting the apical membrane antigen 
1 (AMA1) from Plasmodium falciparum, three laboratories (Oxford, NIH and WRAIR) reported ELISA data in µg/mL that 
were correlated but not concordant. This current study sought to harmonize the methodology used to generate a 
conversion factor (CF) for ELISA analysis of human anti-AMA1 IgG responses across the three laboratories.
Methods: Puriied IgG was distributed to the three laboratories and, following a set protocol provided by NIH, 
AMA1-speciic human IgG was ainity puriied. A new “harmonized CF” was generated by each laboratory using their 
in-house ELISA, and the original clinical trial ELISA data were re-analysed accordingly.
Results: Statistical analysis showed that the data remained highly correlated across all three laboratories, although 
only Oxford and NIH were able to harmonize their CF for ELISA and generate concordant data.
Conclusions: This study enabled two out of the three laboratories to harmonize their µg/mL readouts for the human 
anti-AMA1 IgG ELISA, but results reported from WRAIR are ~ twofold higher. Given the need to validate such informa-
tion for each species and antigen of interest, it is important to bear in mind these likely diferences when interpreting 
µg/mL ELISA data in the future.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria, caused by Plasmodium parasites, continues to 
exert a huge burden on global public health, with over 
200 million clinical cases annually and an estimated 
435,000 related deaths [1]. he development of efective 
and durable vaccines thus remains a key public health 
priority to aid in the on-going global eforts to control 
and eliminate this disease [2].
Numerous stages of the parasite’s lifecycle are suscep-
tible to vaccine-induced antibodies, including the liver-
invasive sporozoite; the red blood cell (RBC)-invading 
merozoite; the infected erythrocyte (iRBC) which dis-
plays cell surface parasite-derived antigen; as well as the 
sexual-stage forms present in both the human host and 
mosquito vector [3]. hese susceptibilities form the foun-
dation of diferent vaccine strategies that seek to prevent 
malaria infection, disease or transmission via the induc-
tion of functional antibodies.
Central to these on-going eforts, and common to each 
strategy irrespective of life cycle stage target, is the need 
to down-select the best-performing vaccine candidates. 
Indeed such candidates can vary widely in terms of their 
vaccine delivery platform, formulation, target antigen(s) 
Open Access
Malaria Journal
*Correspondence:  simon.draper@ndm.ox.ac.uk
†Geneviève M. Labbé and Kazutoyo Miura contributed equally to this 
work
1 The Jenner Institute, University of Oxford, Old Road Campus Research 
Building, Oxford OX3 7DQ, UK
Full list of author information is available at the end of the article
Page 2 of 9Labbé et al. Malar J          (2019) 18:300 
and immunogen design. Consequently, given the com-
plexity of the malaria parasite, vaccine developers under-
taking such studies are often posed with the important 
question: “which antigen is the “best” target for inclu-
sion in a vaccine”? Answering this question is not trivial, 
and poses a number of challenges, especially when com-
parison of vaccine-induced polyclonal antibody (pAb) 
responses is required. Over recent years, researchers 
have, therefore, sought to address this problem through 
careful quantitative analysis of vaccine-induced pAb 
responses. Importantly, by measuring pAb using a mass 
concentration unit readout (typically µg/mL for serum 
IgG), as opposed to arbitrary units (AU) as most often 
reported, it becomes possible to undertake a more 
informed comparison of vaccine-induced pAb that target 
diferent antigens. Indeed, once measured in µg/mL, it 
can be established what concentration of antigen-speciic 
IgG is required to aford a given level of activity using 
functional assays, or a given level of protection in  vivo. 
Head-to-head comparative testing can thus establish 
which antigen performs “the best”—typically that is the 
antigen against which the lowest concentration of pAb is 
required to achieve the desired outcome.
However, although this concept is relatively straight-
forward, it has proved challenging to develop method-
ologies to accurately measure polyclonal antigen-speciic 
IgG responses raised by vaccination of humans or ani-
mals. his is because these responses form only a minor 
fraction of the total circulating IgG in plasma. Indeed in 
humans, for example, the average plasma concentration 
of total IgG is approximately 10 mg/mL, whilst vaccine-
induced antigen-speciic IgG responses are typically 
of the order of tens of µg/mL (although these can vary 
higher or lower by orders of magnitude dependent on 
the vaccine delivery strategy) [4–6]. To address this chal-
lenge, two main methodologies have been established in 
recent years, these are (i) the use of ainity-puriied anti-
gen-speciic and species-speciic IgG ELISA standards 
[7], or (ii) to undertake calibration-free concentration 
analysis (CFCA) on a Biacore system [8]. Both experi-
mental approaches ultimately generate conversion factors 
(CF), that allow for the typical IgG ELISA AU readout to 
be converted into a mass concentration (routinely µg/
mL). hey also both require careful setup and assess-
ment, and these studies need to be performed for each 
new vaccine antigen and target species IgG combination.
Apical membrane antigen 1 (AMA1) is a micronemal 
protein, expressed by the blood-stage malaria merozo-
ite and a long-standing candidate vaccine antigen [9]. 
A range of diferent AMA1 based-vaccines have been 
assessed in Phase I/II clinical trials over the last decade. 
In 2016 a Phase I/IIa clinical trial (called VAC054) was 
reported, testing the recombinant AMA1 protein vaccine 
(FMP2.1) formulated in GlaxoSmithKline (GSK)’s Adju-
vant System 01 (AS01). In this study, serum samples 
were analysed independently for anti-AMA1 human 
IgG antibodies by three diferent laboratories (at Oxford, 
NIH and WRAIR) using in-house ELISAs and recombi-
nant AMA1 protein [10]. ELISA results in AU from each 
laboratory were then converted into μg/mL concentra-
tions of anti-AMA1 IgG antibody using CFs that had 
been independently and historically established [6, 7, 
11]. Although these results were highly correlated, they 
were not concordant (Additional ile 1: Figure S1). Given 
the importance of ensuring accurate reporting of µg/mL 
concentrations, this present study aimed to harmonize 
the methodology used to generate the CF, and to assess 
whether this led to concordance of results between the 
three laboratories.
Methods
Human anti‑AMA1 vaccine trial sera
he details of the VAC054 Phase I/IIa clinical trial have 
been published previously [10]. In brief, 15 healthy adult 
volunteers in the UK were immunized by intramuscular 
injection with a 50  µg dose of FMP2.1 protein vaccine 
formulated in AS01 adjuvant from GSK on days 0, 28 
and 56. Twelve out of the 15 vaccinated volunteers then 
underwent blood-stage controlled human malaria infec-
tion (CHMI) 2 weeks after the inal vaccination (on day 
70) to assess vaccine eicacy. Following completion of 
this study, six 10 mL serum pools were prepared (using 
ELISA data from the VAC054 trial in order to cover 
a range of anti-AMA1 responses) and also including 
a pool of naïve (day 0) sera. Samples were labelled 1 to 
6 in increasing order, with 1 being the naïve pool and 6 
being the highest response pool. he VAC054 trial was 
registered with Clinicaltrials.gov (NCT02044198) and 
was conducted according to the principles of the current 
revision of the Declaration of Helsinki 2008 and in full 
conformity with the International Conference on Harmo-
nization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use guidelines for good clin-
ical practice. he VAC054 study received ethical approval 
from the UK NHS Research Ethics Service (Oxfordshire 
Research Ethics Committee A, Ref 13/SC/0596), and the 
Western Institutional Review Board (WIRB) in the USA 
(Ref 20131985). he study was approved by the UK Med-
icines and Healthcare products Regulatory Agency (Ref 
21584/0326/001-0001).
Total IgG puriication
Total IgGs were puriied at NIH from each serum pool 
using protein G columns according to the manufactur-
er’s instructions (Pierce, Inc., Rockford, IL). he eluted 
fractions were immediately neutralized with Tris bufer 
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(pH 9.0), dialyzed against RPMI 1640 medium (hermo 
Fisher Scientiic, UK), and concentrated with centrifugal 
ilter devices to a concentration of 40 mg/mL. Total IgG 
from each pool was then divided into three fractions and 
distributed to the three laboratories participating in the 
study.
AMA1‑speciic IgG puriication
In each laboratory, AMA1-speciic antibodies were iso-
lated from total IgG aliquots using ainity puriication 
columns, according to a protocol established by NIH.
First, the puriication column was packed as follows: 
after adding the bottom frit to a disposable 10  mL col-
umn (Pierce) and 1 mL NHS-activated Sepharose slurry 
(product code 17-0906-01, GE Healthcare Life Sciences, 
Buckinghamshire, UK), 15  mL ice-cold 1  mM HCl was 
passed through the column to wash the slurry. Sepha-
rose beads were resuspended with a mixture of 0.5  mL 
FMP2.1 AMA1 protein (provided by WRAIR) [12] at 
1  mg/mL in PBS plus 0.25  mL coupling bufer (0.2  N 
 NaHCO3, 0.5  N NaCl, pH 8.3). he column was sealed 
with parailm and left rocking overnight at 4  °C. Next 
day, at room temperature (RT), the coupling bufer was 
drained and 5 mL blocking bufer (0.5 M ethanolamine, 
0.5  M NaCl, pH 8.3) was passed through the column. 
After capping the bottom of the column, 10 mL blocking 
bufer was added; the top of the column was then capped 
and the column left rocking for 3  h at RT. he column 
was then centrifuged at 200 xg for 10  min, top frit was 
placed and blocking bufer drained. he column was 
then washed thrice with 2  mL blocking bufer, followed 
by three rinses with 2 mL wash bufer (0.1 M acetic acid, 
0.5 M NaCl, pH 4), then another three rinses with block-
ing bufer. After capping the bottom of the column, 2 mL 
blocking bufer was added, left for 15 min, then drained. 
he column was again washed three times with 2  mL 
wash bufer, three times with 2 mL blocking bufer, and 
three times with 2 mL wash bufer. Next, 5 mL binding 
bufer (50  mM  Na2HPO4, pH 7.0) was passed through 
the column, followed by 5 mL 20% ethanol, of which only 
about 3 mL was drained before capping the column for 
storage at 4 °C.
Subsequently, ainity adsorption was performed as fol-
lows: total IgG (0.5–0.9  mL of each sample, 40  mg/mL 
stocks) was mixed with 9 volumes of room-temperature 
binding bufer. he column was washed with 5 mL room-
temperature binding bufer and 5 mL room-temperature 
elution bufer (0.1  M glycine, pH 2.7), and equilibrated 
with 5  mL binding bufer. After placing a clean tube to 
collect low-through, the irst sample (naïve pool) was 
applied to the column, and low-through re-applied 4 
extra times to ensure complete binding. he column was 
then washed with 10 mL binding bufer. AMA1-speciic 
IgG were eluted with 5  mL elution bufer into a 15  mL 
tube containing 300 µL of 1 M Tris, pH 9.0. Upon imme-
diate mixing, IgG were stored at 4  °C. he column was 
then washed with 5  mL elution bufer, re-equilibrated 
with 5  mL binding bufer, and the second sample was 
applied as described above. he same procedure was fol-
lowed for samples 3, 4, 5 and 6, in this order. he column 
was then rinsed and stored in 20% ethanol at 4 °C.
Subsequently, AMA1-speciic IgG were dialyzed 
against RPMI 1640 and concentrated to 50–100 µL inal 
product: for each sample, 4  mL of elution fraction was 
applied to an Amicon Ultra-4 Centrifugal Filter Unit 
(30  kDa membrane EMD Millipore, Cat # UFC803024) 
and spun at 3000–4000×g at 4 °C for 10 min. After dis-
carding the low-through, the left-over 1 mL elution frac-
tion was added to the ilter and spun for 20-30 min until 
100–150 µL remained above the ilter. Flow-through was 
discarded, and RPMI 1640 medium was used to ill the 
device up to 4  mL, mixed with the sample, and centri-
fuged until 100–150 µL remained above the ilter. RPMI 
1640 was again added to 4  mL, mixed and centrifuged, 
aiming for a inal volume of 50–100 µL. Concentrated 
IgG was then transferred into a 0.5 mL sterile tube and 
stored at 4  °C. Finally, the concentration of AMA1-spe-
ciic IgG was measured by absorbance at 280  nm using 
NanoDrop (NanoDrop, Wilmington, DE, USA).
AMA1 proteins and ELISA methods
For each eluted AMA1-speciic fraction, the anti-AMA1 
antibody response in AU was measured by each labora-
tory, using the same ELISA protocol as they had used for 
the analyses of the VAC054 clinical trial [10]; i.e., each 
laboratory determined AUs using their own protocol and 
AMA1 protein, unless speciied otherwise. he difer-
ences in the human anti-AMA1 IgG ELISA procedures 
in the three laboratories are summarized in Additional 
ile 1: Table S1. he WRAIR protein, FMP2.1, is a recom-
binant AMA1 from the 3D7 clone of Plasmodium falci-
parum produced in and puriied from Escherichia coli, 
carrying hexa-histidine (His6) tags both N- and C-termi-
nally [12]. he NIH protein, AMA1-3D7 (lot MV#1183), 
was produced in Pichia pastoris and carries a C-terminal 
His6-tag [13]. he Oxford protein, PfAMA1 (3D7).BAP.
HIS (lot P0146), was produced in mammalian HEK293 
cells as previously described [6]. All proteins included the 
full AMA1 ectodomain.
AMA1 protein comparison by ELISA at Oxford
hree Nunc-immuno maxisorp plates were coated with 
2  μg/mL Oxford, NIH, or WRAIR AMA1 protein in 
DPBS. he same independent standard curve (10 points) 
was run on each plate in duplicate, using a previously 
described high-titer anti-AMA1 human serum reference 
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sample [14]. Otherwise, the same ELISA method for 
this experiment was performed on all three plates in 
parallel: plates were left at RT overnight, then washed 6 
times with PBS containing 0.05% Tween 20 (PBS/T) and 
blocked for 1 h with Casein block solution (Pierce). After 
another wash step, samples were added to each plate for 
2 h. Plates were washed again and alkaline phosphatase-
conjugated goat anti-human IgG (γ-chain) (Sigma) 
diluted 1:1000 in Casein block solution was added for 1 h, 
before development with p-nitrophenylphosphate sub-
strate (Sigma) diluted in diethanolamine bufer (hermo 
Fisher Scientiic). Optical density at 405 nm  (OD405) was 
read using a microplate reader (Biotek) and Gen5 v1 
software.
Statistical analysis
To determine the new, harmonized conversion factor 
(CF; mass concentration of antibody which gives 1 AU), 
a linear regression was performed using AU and pro-
tein concentration of AMA1-speciic IgGs generated in 
this study (calibration data set). Subsequently, AU val-
ues for 12 dC-1 (day 69, the day before CHMI) samples 
of VAC054 study measured in each laboratory (reported 
previously [10]) were multiplied by the laboratory-spe-
ciic CF, in order to transform the antibody level of each 
sample tested in each laboratory into mass concentration 
(MC data set). he MC data sets between two laborato-
ries were used to determine the concordance correlation 
coeicient (CCC), more speciically RMAC version of 
the concordance coeicient, as described previously [15]. 
To determine conidence intervals for the CCC, best-it 
slope, and Pearson’s correlation coeicient of MC data 
sets among diferent laboratories, considering errors in 
both CF and AU determinations, a bootstrap method was 
used. Speciically, the following steps were performed: (i) 
choose a random sample with replacement from the cali-
bration data set, calculate CF for each laboratory using 
a linear regression; (ii) choose a random sample with 
replacement from the MC data set except replace the CF 
originally used with the CF determined from step (i) for 
each laboratory. In step (ii), paired MC data samples were 
selected for all labs. For example, if sample # 1, 2, 2, 4, 5 
and 6 of the MC data set were randomly selected from 
a laboratory, then sample # 1, 2, 2, 4, 5 and 6 from the 
other two laboratories were used for analysis; (iii) calcu-
late pairwise CCC, best-it slope, and Pearson’s correla-
tion coeicient using the step ii data set; (iv) repeat steps 
(i)–(iii) 10,000 times, then use the 95% BCa bootstrap 
interval from those replicates [16]. Conidence intervals 
were inverted to get P values.
In separate analyses, to compare the MC data set from 
the three laboratories, a Friedman test followed by Wil-
coxon signed rank test was used. To compare OD values 
of the serially diluted anti-AMA1-3D7 anti-serum pool 
tested in a single laboratory (Oxford), but against three 
diferent proteins, linear regression analyses were per-
formed, and slope,  R2 and P value (whether the slope is 
signiicantly diferent from 1) were calculated.
Analyses were performed using GraphPad Prism ver-
sion 7.03 for Windows (GraphPad Software Inc., Cali-
fornia, USA) and R version 3.3.2. A P value < 0.05 was 
considered signiicant.
Results
Six pools of 10  mL serum samples were generated in 
Oxford from vaccinees in the VAC054 trial. Samples were 
selected from various time-points and volunteers so as to 
generate a spread of anti-AMA1 IgG responses across the 
six diferent pools. One of the six pools was pre-immuni-
zation (day 0) serum. he sera were provided to NIH who 
performed protein G puriication of each sample, prior to 
distribution of one aliquot of each puriied IgG to Oxford 
and WRAIR.
Each laboratory subsequently processed and analysed 
each sample according to a set protocol provided by NIH. 
Initially, AMA1-speciic IgG were ainity-puriied from 
each sample using FMP2.1 protein, which was used in 
the VAC054 trial, coupled to columns as described in 
the Methods section, prior to bufer exchange and con-
centration. he concentration of each ainity-puriied 
AMA1-speciic IgG was measured by Nanodrop and 
analysed by the in-house ELISA protocol at each labora-
tory (Additional ile 1: Table S1), using in-house AMA1 
protein as a coating antigen for ELISA. IgG concentra-
tion was then plotted against ELISA AU and the slope 
of each linear regression line was used as the new “har-
monized conversion factor (CF)” (Fig.  1). Subsequently, 
these harmonized CFs were used to re-analyse the origi-
nal VAC054 ELISA data (Additional ile 1: Fig. S1), thus 
reporting the amount of AMA1-speciic human IgG per 
ELISA AU in µg/mL (Fig. 2). In the analysis, a ixed har-
monized CF (i.e. the best estimate value) for each labora-
tory was utilized. he median [range] of the 12 responses 
were: Oxford = 132 [60–215] µg/mL; NIH = 105 [54–219] 
µg/mL; and WRAIR = 219 [80–448] µg/mL. Notably, 
when antibody levels in the µg/mL scale were compared 
from the three laboratories, there was a signiicant dif-
ference among the three (P < 0.0001; Friedman test), and 
the diferences of all three comparisons were signiicant 
(P = 0.003 for Oxford vs. NIH; P = 0.0005 for WRAIR vs. 
Oxford or NIH).
Since the above statistical analysis did not account 
for the error in the harmonized CF determinations (see 
Fig. 1 for the 95% CI for each CF), further bootstrap anal-
ysis was performed to compare the data from the three 
laboratories. he results indicated that the new ELISA 
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data in mass concentration between WRAIR and both 
Oxford and NIH remained non-concordant when apply-
ing the harmonized CFs (Table 1), despite all three data-
sets showing a strong correlation. However, there was 
strong concordance of ELISA data (n = 12) between NIH 
and Oxford laboratories when applying their harmo-
nized CFs (CCC = 0.898 [95% CI 0.580, 0.971], Table 1). 
hus overall, this study had enabled two out of the three 
laboratories to harmonize their µg/mL readouts for the 
human anti-AMA1 IgG ELISA.
To uncover the mechanism of discrepancy, the three 
recombinant AMA1 proteins used by the different 
laboratories were compared side-by-side in an ELISA 
conducted at Oxford. At NIH, the protein was pro-
duced in Pichia pastoris yeast [13]; at Oxford, AMA1 
protein was produced in a mammalian HEK293 cell 
system [6]; and at WRAIR, the FMP2.1 AMA1 pro-
tein was produced in Escherichia coli [12]. The same 
test sample was assessed using identical methodology 
on plates coated with AMA1 protein provided by each 
Fig. 1 Conversion factors determined using the harmonized method. Six total IgG samples from the VAC054 trial were divided amongst the three 
laboratories and used to determine conversion factors. AMA1-speciic IgG was ainity-puriied using the same protocol and FMP2.1 protein coupled 
to puriication columns. The concentration of thus ainity-puriied AMA1-speciic IgG in ng/mL was plotted against ELISA AU obtained using 
in-house ELISA protocols with in-house AMA1 protein. The slope of each linear regression line was used as the “harmonized conversion factor” (CF)
Fig. 2 VAC054 ELISA data using harmonized conversion factors. 
The original VAC054 ELISA data for the day before CHMI (dC-1) 
were re-analysed using the new harmonized CFs. Twelve vaccinees 
underwent CHMI and their anti-AMA1 serum IgG responses are 
reported. Individual responses are shown with a connecting line for 
each sample
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of the three laboratories. Analysis by linear regression 
highlighted small, but significant, differences (Fig.  3). 
In particular, for the same antibody samples tested, the 
WRAIR coat protein generally gave lower  OD405 read-
ings compared to NIH/Oxford and it appeared that 
the two highest data points on the WRAIR OD axis 
were drifting towards saturation at around  OD405 = 2 
(Fig. 3).
Table 1 Statistical analysis of harmonized data
Bootstrap analysis of the new ELISA data in mass concentration scale was undertaken (n = 12) to assess for concordance. Linear regression and correlation analyses are 
also shown. The 95% conidence intervals (CI) were calculated using percentiles from 10,000 bootstraps
a Testing the null hypothesis of slope = 1
Laboratory Oxford vs. WRAIR Oxford vs. NIH NIH vs. WRAIR
Concordance
Concordance coeicient (CC) 0.2987 0.8979 0.1693
Bootstrap 95% CI (− 0.2105, 0.5635) (0.5796, 0.9713) (− 0.4382, 0.5359)
P value 0.2398 0.0064 0.6441
Linear regression
Slope 0.5034 0.9381 0.5095
Bootstrap 95% CI (0.3663, 0.8545) (0.7418, 1.3191) (0.3490, 0.8517)
P  valuea 0.0096 0.5933 0.0148
Correlation
Pearson’s correlation coeicient 0.9036 0.9489 0.904
Bootstrap 95% CI (0.8098, 0.9820) (0.8975, 0.9850) (0.8023, 0.9927)
P value 0.0082 0.0002 0.0082
Fig. 3 ELISA comparison of AMA1 proteins used by Oxford, NIH and WRAIR. The same anti-AMA1 antiserum was assessed by ELISA using identical 
methodology (Oxford method) on plates coated with AMA1 protein provided by each of the three laboratories (Oxford, NIH and WRAIR). The test 
sample was plated in a dilution series, and the points show the mean of duplicate readings. Linear regression analysis of  OD405 nm readings is 
shown. The linear regression line was forced to go through point (X = 0, Y = 0). aTesting the null hypothesis of slope = 1
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Discussion
his current study sought to assess whether the method-
ology used to generate a CF for ELISA analysis of human 
anti-AMA1 IgG responses across three laboratories 
could be harmonized. Historical data from the VAC054 
trial showed the data from Oxford, NIH and WRAIR 
were correlated but not concordant, suggesting a dis-
crepancy in the CFs used to convert ELISA AU to µg/
mL. he ability to report vaccine-induced IgG responses 
in terms of µg/mL, as opposed AU, is highly informative, 
enabling i) a better understanding of the magnitude of 
the immune response, and ii) better comparison between 
vaccines targeting diferent antigens. However, these 
interpretations rely on the accuracy of the CF which is 
used to generate ELISA data in µg/mL, and it is impor-
tant to establish whether independent laboratories can 
achieve concordant data.
Six serum pools were initially prepared from the 
VAC054 clinical trial in Oxford and the total IgGs were 
then puriied at NIH, before distribution to the three 
laboratories participating in the study. Using a set pro-
tocol provided by NIH, AMA1-speciic human IgG were 
independently ainity-puriied from each sample using 
FMP2.1 protein provided by WRAIR. A new “harmo-
nized CF” was generated by each laboratory using their 
in-house AMA1 protein as a coating antigen for ELISA 
and the original VAC054 clinical trial ELISA data were 
re-analysed accordingly. As shown in Fig.  1, the proto-
col of “harmonized CF” determination used in this study 
provided a strong linear correlation between ELISA units 
and antigen-speciic protein concentration in each of the 
three laboratories  (R2 > 0.975). he results thus indicated 
the antigen-speciic IgG ainity puriication protocol 
could provide the accurate estimate of CFs in diferent 
laboratories. However, compared to CFCA for example, 
this method requires larger amounts of antigen and anti-
sera. herefore, the best methodology to determine a CF 
should be selected depending on the goal of the study and 
availability of test materials. he reproducibility between 
laboratories of other methods, such as CFCA, has not yet 
been assessed, although one small analysis from Oxford 
showed comparable results between the two methods [6].
he initial analysis was undertaken as traditionally 
done in the literature—using the deined point esti-
mate of the harmonized CF to convert AU data to µg/
mL (Fig.  1). In this case, the median and range of the 
datasets from Oxford and NIH were very comparable, 
however, the dataset from WRAIR showed a roughly 
twofold higher median and twofold greater range 
(Fig.  2). Statistical analysis by Friedman test followed 
by Wilcoxon signed rank tests, however, also reported 
that the datasets were all signiicantly diferent. he 
signiicant diference between the Oxford and NIH 
datasets was due to systematically smaller (but not by 
much, see Fig.  2 and Additional ile  1: Fig. S1) meas-
urements from the NIH. his result did not account for 
the size of the diferences or the variability in estimates 
of the harmonized CFs. When those two efects were 
accounted for by the subsequent bootstrap analysis of 
the data (Table  1), there was strong concordance of 
ELISA data between the NIH and Oxford laboratories 
when applying their harmonized CFs (CCC = 0.898 
[95% CI 0.580, 0.971]). On the contrary, the dataset 
from WRAIR had much smaller and non-signiicant 
estimates of concordance, but was still closely corre-
lated with the datasets from NIH and Oxford.
Although this enabled two out of the three laborato-
ries to harmonize their µg/mL readouts for the human 
anti-AMA1 IgG ELISA, the lack of strong concordance 
between the NIH/Oxford datasets and the data from 
WRAIR was not explained. Small, but signiicant, dif-
ferences were noted in the  OD405 response of the three 
AMA1 proteins used for in-house ELISAs which poten-
tially contributed to this result (Fig. 3). hese proteins 
were made historically and have small diferences in 
terms of amino acid sequences and each is made in a 
diferent expression platform (bacterial, yeast versus 
mammalian cells). he diference in ODs among difer-
ent proteins (Fig. 3) could be partially explained by the 
characteristics of them (binding capacity to the ELISA 
plates, glycosylation modiication, etc.). However, the 
diference in OD values among the three AMA1 pro-
teins was only 10–20% (the best-it slopes were 0.806 to 
1.100), which might be too small to explain the ~ two-
fold diference in µg/mL readouts (Table 1). In addition, 
WRAIR protein on the plate may ofer a lower dynamic 
range at higher antibody concentrations, as lower reso-
lution of some data points was also observed along the 
line of best it in Fig. 1. he other factors which might 
contribute to the discrepancy (at least in part) could be 
the diferences in batches of commercial reagents and 
ELISA protocols used at the diferent sites. It would be 
ideal to determine whether the ~ twofold diference in 
µg/mL readouts among three laboratories is a repro-
ducible phenomenon and to uncover the mechanism of 
this diference experimentally. However, human anti-
AMA1 antibodies from the study are very limited and it 
is now diicult to perform such additional studies. For 
now, it remains that the human anti-AMA1 IgG ELISA 
readout in µg/mL from WRAIR is approximately two-
fold higher than that from Oxford and NIH, and thus 
this diference should be held in mind when interpret-
ing clinical trial ELISA data in the literature.
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Conclusion
his study attempted to harmonize CFs to achieve con-
cordant ELISA measurements in µg/mL for one species 
(human) and antigen (AMA1) between three independ-
ent laboratories using the antigen-speciic IgG ainity 
puriication methodology. Although successful across 
two laboratories, there was not strong concordance 
across all three, despite achieving highly correlated 
ELISA data. he reasons for these diferences remain to 
be fully determined, however our study underlines the 
di culties associated with determining µg/mL readouts 
for antigen-speciic ELISAs. his study suggests that 
determining the harmonized CFs may not be suicient 
to obtain concordant results from diferent laboratories. 
More stringent harmonization (e.g., sharing the same 
protein and using the same protocol for each step) would 
be required. While that is the ideal scenario, given the 
need to validate such procedures for each species and 
antigen of interest, and the possibility that the studies 
could be conducted with multiple diferent antigens, it 
might be practically challenging to perform all studies in 
a “harmonized” fashion. herefore, it is important to bear 
in mind these likely diferences when interpreting data 
from diferent studies in the future.
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